Navigation Links
Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
Date:1/14/2008

PHILADELPHIA, Jan. 14 /PRNewswire/ -- Kibow Biotech, Inc. is pleased to announce that it has been granted an International Patent Cooperation Treaty (PCT) patent from Australia, China and India. The approved patent, "Prebiotic and Probiotic Compositions and their Method of use for Gut-based Therapy," protects the composition and method behind the Company's oral probiotic product formulation (Kibow Biotics(R)) which may significantly reduce concentrations of several nitrogenous waste metabolites that accumulate in renal deficiency. The serial numbers for this patent are: 20022342641 (Australia), ZL 02810078.6 (China) and 1029/MUMNP/2003, 205478 (India). Kibow Biotech has an identical PCT patent pending in Canada, the European Union, Japan, and South Korea.

In addition, the term "Enteric Dialysis(TM)" has been recognized as a registered service trademark by the patent and trademark authority of the Government of India. "Enteric Dialysis(TM)" designates the technology behind the Company's proprietary probiotic product formulation which has the ability to eliminate uremic nitrogenous waste metabolites via the gut route.

Kibow Biotech has another PCT application, "Compositions and Methods for Augmenting Kidney Function," under national review in all of the aforementioned countries except Australia where this patent has also been approved (#2002255717).

Dr. Natarajan Ranganathan, VP (R&D) and interim CEO, stated, "In addition to our PCT patents, Kibow has already obtained three US patents, with four more additional patents under examination process. The rapidly expanding intellectual property portfolio for our unique 'Enteric Dialysis(TM)' platform technology has added immense potential to our company products for kidney failure applications worldwide."

About Kibow Clinical Trials

Currently Kibow has begun pilot-scale human clinical studies of its uremic formulation (Kibow Biotics(R)) in six different sites and five countries. his is a short-term (six-month) double-blind, placebo-controlled, cross-over study mainly designed to establish the safety (US FDA's Generally Recognized as Safe ("GRAS") status) and pre-market notification of its intended uremic syndrome applications. In addition, this clinical trial is evaluating the possible use of Kibow Biotics(R) as a dietary or nutritional supplement for chronic kidney failure (stage III and IV) predialysis patients worldwide.

For more information, visit http://www.kibowbiotech.com

Forward-looking statements

This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Kibow Biotics(R), for kidney failure applications, and the possible benefits of Kibow Biotics in slowing the progression of chronic kidney failure or helping patients feel better. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Kibow Biotics will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Kibow Biotics(R) may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Kibow Biotics(R). Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company; risks associated with completing clinical trials of product candidates; the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward- looking statements except as required by law.

CONTACT:

Dr. Natarajan Ranganathan

CEO and VP Research and Development

Tel: 1 (610) 353 5130

Web site: http://www.kibowbiotech.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Kibow Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
2. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
3. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
4. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
7. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Chinese SFDA Grants Immtech Fast Track Status
11. Tainted Chinese Food Ingredients First Discovered in 2005
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing ... this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which ... inflammation. The data will be shared in a ... at ODAC, which is being held Jan. 13-16 in ... ...
(Date:1/12/2017)...   TyrNovo , s NT219 drug candidate ... cancer drug resistance and would be ... NT219 is a novel proprietary ... ( IRS1/2 and STAT3) highly involved in ... .   NT219 has demonstrated ...
(Date:1/12/2017)... -- "Global Lung Cancer Vaccine Market & Pipeline ... trends in the global lung cancer vaccine market. ... available in the market. This report analyzes the ... in clinical pipeline and gives comprehensive clinical insight ... the lung cancer vaccines. Currently there are 9 ...
Breaking Medicine Technology:
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in ... March 3-4, 2017. This Congress is expertly designed to meet the educational needs ... with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at ...
(Date:1/13/2017)... ... ... inventor from Pahrump, Nev., used an unsavory medical experience to think of a way to ... urine bag for a half year due to lazy bladder," he said. "Keeping these things ... better way to do this." , He then designed and created a prototype of the ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
(Date:1/13/2017)... ... January 13, 2017 , ... As the nation watches this month’s transition ... colleges and schools of education across the country is urging a fundamental reconsideration of ... Principles released today, 175 deans sounded the alarm: “Our children suffer when we deny ...
(Date:1/13/2017)... ... January 13, 2017 , ... One way to obtain a green card is ... can show their work is in the national interest. There are two significant advantages ... be sponsored by an employer; and 2) the submission is made directly to the ...
Breaking Medicine News(10 mins):